India Insulin Delivery Devices Market By Product Type (Pens, Pumps, Pen Needles, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By End User (Hospitals & Clinics, Homecare, Others), By Region, Competition, Forecast and Opportunities, 2020-2030F

Market Overview

India Insulin Delivery Devices Market was valued at USD 1.06 Billion in 2024 and is expected to reach USD 1.68 Billion by 2030 with a CAGR of 7.90% during the forecast period. Insulin delivery devices constitute essential medical tools and systems designed to administer insulin, a hormone critical for regulating blood sugar levels in individuals with diabetes. These devices facilitate the controlled and precise administration of insulin to maintain blood sugar within target ranges. Among these devices are insulin pens, resembling pens in shape and size, which offer easy and accurate dose settings through pre-filled or replaceable insulin cartridges. Insulin pumps, small electronic devices, provide a continuous insulin supply via a catheter inserted under the skin, allowing for precise control with adjustable basal rates and bolus doses. Additionally, microneedle patches, utilizing tiny needles for painless insulin delivery through the skin, offer a less invasive alternative to injections.

The preference for insulin delivery devices such as pens and pumps over traditional syringes and vials is driven by factors like ease of use, convenience, and improved quality of life for patients. Continuous innovation in device technology, including smart pumps and connected devices, further boosts their adoption rates by enhancing diabetes management. Increasing awareness about diabetes, its complications, and the significance of proper management fuels the demand for insulin delivery devices. Healthcare providers and organizations play a vital role in this process through patient education programs, helping individuals gain a better understanding of diabetes management, including the utilization of insulin delivery devices.

Key Market Drivers

Technological Advancements

Smart insulin pens are equipped with Bluetooth connectivity and smartphone apps, enabling them to record insulin doses, share data with healthcare providers or caregivers, and provide dose reminders. This technology facilitates patient monitoring of insulin usage and adherence to treatment plans. Insulin pumps have evolved with features like closed-loop systems (artificial pancreas) that automatically adjust insulin delivery based on continuous glucose monitoring (CGM) data, maintaining stable blood sugar levels and reducing the risk of hypoglycemia and hyperglycemia. Integration with CGM systems allows for more precise insulin delivery based on real-time glucose data, enhancing remote monitoring and communication with healthcare providers.

Advancements in needle technology have led to thinner and shorter needles, improving patient comfort during injections. Some devices utilize microneedles or spring-loaded mechanisms for a less painful experience. Customizable insulin delivery profiles based on factors like physical activity and meals personalize diabetes management. For instance, in October 2023, researchers led by Prof. T. Govindaraju from the Bioorganic Chemistry Laboratory at JNCASR, Bengaluru, developed a silk-based hydrogel system that mimics the pancreas for more efficient insulin delivery in diabetes treatment. This innovative system addresses challenges faced by individuals with Type 1 and advanced Type 2 diabetes by releasing insulin in response to blood glucose levels. The system encapsulates insulin in silk protein “fibroin,” forming a gel under the skin that gradually diffuses insulin over five days. Further modifications created a smart system that releases insulin when glucose levels rise, offering a controlled and continuous insulin supply. The study published in ACS Applied Materials and Interfaces mimics the pancreas' function, providing an automated, self-regulating insulin release to help manage blood sugar levels effectively. AI algorithms analyze CGM data to predict blood sugar fluctuations, suggest insulin dosage adjustments, and alert users to potential issues, enhancing diabetes control.Closed-loop insulin delivery systems automatically adjust insulin delivery in response to glucose levels, minimizing manual intervention. Patch insulin delivery devices offer discreet and continuous insulin delivery, ideal for wear on the skin.

Telemedicine platforms and remote monitoring technologies allow healthcare providers to remotely monitor patients' glucose levels and insulin delivery, particularly important during pandemics like COVID-19. Modern insulin delivery devices feature user-friendly interfaces with touchscreen displays and intuitive menus, facilitating ease of use for patients. Real-time data sharing with caregivers or healthcare providers and alerts for extreme blood sugar fluctuations enhance safety and care coordination. Improved battery technology extends device usage times and reduces maintenance requirements, fostering the development of the India Insulin Delivery Devices Market.

Shifting Patient Preference for Insulin Delivery Devices

Patients often favor insulin delivery devices that prioritize user-friendliness and simplicity. Devices like insulin pens and pumps are specifically designed for ease of use, appealing to patients who may feel hesitant about self-administering insulin. Pain reduction during injections is a key consideration, with insulin delivery devices, particularly pen needles, engineered to minimize discomfort. This feature enhances treatment adherence. Insulin pens and pumps offer added convenience, being discreet and portable, enabling patients to administer insulin doses in various settings, fostering flexibility in their daily routines. The precision of dosing provided by these devices is valued by patients for effective diabetes management. Additionally, the discreet nature of insulin pens and pumps helps mitigate potential social stigma associated with diabetes, promoting a sense of normalcy.

Insulin pumps offer enhanced dose flexibility, empowering patients to adjust basal rates and bolus doses according to their individual needs. Personalization features in some devices allow patients to tailor their treatment to suit their lifestyle. Modern insulin delivery devices, particularly those with Bluetooth connectivity, enable patients to monitor insulin usage and blood sugar levels via smartphone apps, promoting engagement in their care. Devices that improve overall quality of life by minimizing the frequency of injections are highly favored. The freedom and flexibility offered by insulin pumps and similar devices positively impact patient well-being. Increasingly, patients seek devices that facilitate remote monitoring and data sharing with healthcare providers or caregivers, aligning with the trend toward telemedicine and remote healthcare.

Patients value having a choice in their treatment decisions and prefer insulin delivery devices that cater to their preferences and lifestyle. Positive feedback and recommendations from other patients or healthcare professionals can significantly influence patient preference for specific insulin delivery devices. These factors are expected to drive demand in the India Insulin Delivery Devices Market.

Increasing Healthcare Awareness

As healthcare awareness expands, more individuals gain knowledge about diabetes, its risk factors, and the significance of effective management. This education often encompasses various insulin delivery methods, fostering a better understanding of devices like insulin pens and pumps. Healthcare awareness initiatives prompt people to undergo regular health check-ups, including diabetes screenings. Early diagnosis often leads to the initiation of insulin therapy, consequently increasing the demand for insulin delivery devices.

Healthcare awareness campaigns also inform individuals about available treatment options for diabetes. Informed patients can make more educated decisions regarding their treatment methods. Understanding the complications associated with diabetes, such as cardiovascular disease and neuropathy, motivates individuals to prioritize their diabetes management. Insulin delivery devices play a crucial role in achieving better glycemic control, thus reducing the risk of complications. Well-informed patients are more likely to adhere to their treatment plans, and insulin delivery devices can simplify this process, enhancing patient compliance and improving health outcomes. The dissemination of information about technological advancements in healthcare drives patients to seek the latest and most advanced insulin delivery devices offering improved ease of use and better diabetes control. Healthcare awareness initiatives also emphasize preventive measures to mitigate the risk of chronic conditions like diabetes. Despite preventive efforts, individuals may have family members or acquaintances with diabetes, leading to increased demand for insulin delivery devices.

Improved healthcare awareness facilitates better access to healthcare services, including diabetes management, resulting in increased demand for insulin delivery devices as patients have more opportunities to discuss treatment options with healthcare providers. Healthcare professionals play a crucial role in educating patients about diabetes and insulin delivery devices, influencing patient preferences. Empowered patients become more proactive in managing their health, driving interest in exploring different insulin delivery options and advocating for their preferences. Community support for individuals with diabetes, fostered by support groups and educational programs, encourages the exchange of information, including experiences with insulin delivery devices, further fueling demand for these devices. This trend is expected to accelerate the demand for insulin delivery devices in the India market.

Download Free Sample Report

Key Market Challenges

Counterfeit Products

Counterfeit insulin delivery devices can compromise patient safety. Patients may unknowingly use substandard or ineffective devices, putting their health at risk. Substandard insulin delivery devices can lead to incorrect dosing, poor glycemic control, and adverse events. The presence of counterfeit products affects the market by undermining the revenue of legitimate manufacturers and distributors. This can lead to financial losses for the industry and reduced incentives for investment in research and development of new and improved devices. The presence of counterfeit insulin delivery devices can damage the reputation of established brands and manufacturers. Patients and healthcare providers may lose trust in the authenticity and quality of these devices. Counterfeit products can create unfair competition in the market. Legitimate manufacturers face challenges in competing with counterfeit products that may be available at lower prices due to reduced quality control and safety standards. Counterfeit products can evade regulatory oversight and quality control measures. This undermines efforts by regulatory authorities to ensure the safety and efficacy of medical devices. The use of counterfeit insulin delivery devices can have severe public health implications, particularly when it results in adverse health outcomes or treatment failures for patients with diabetes.

Cultural Beliefs and Stigmas

In many Indian cultures, traditional remedies and alternative therapies hold deep-rooted significance. Some individuals may prefer traditional treatments over Western medicine, including insulin therapy. This can lead to delayed or inadequate diabetes management. A common cultural stigma is a fear of needles and injections. Many people with diabetes may avoid insulin therapy, especially if it involves syringes or needles. This can deter the adoption of insulin delivery devices. Cultural beliefs and misconceptions about diabetes and insulin can create barriers to proper treatment. Some individuals may associate diabetes with negative connotations or believe that insulin is harmful, leading to resistance in using insulin delivery devices. Stigmatization of individuals with diabetes can lead to secrecy and reluctance to openly discuss the condition. This can prevent patients from seeking the best treatment options, including insulin delivery devices. Cultural dietary practices can affect diabetes management. Patients may struggle to adapt their traditional diets to their treatment plans, potentially affecting the effectiveness of insulin therapy. Cultural factors may contribute to a lack of awareness about diabetes and its management. Patients may not be well-informed about the available insulin delivery options. Family dynamics and cultural norms can influence healthcare decisions. In some cases, family members may be resistant to accepting insulin therapy for a loved one, leading to treatment delays.

Key Market Trends

Customization and Personalization

Manufacturers were offering a wider range of insulin delivery devices to accommodate individual preferences. This includes insulin pens, insulin pumps, patch pumps, and more. Patients could choose the device that aligns with their lifestyle and comfort. Insulin pumps with the ability to set variable basal rates gained popularity. Patients could personalize their insulin delivery based on their daily routines, physical activity, and other factors that affect insulin requirements. Customizable bolus dosing features allowed patients to adjust insulin doses before or after meals, depending on their specific dietary habits and glucose levels. Many insulin delivery devices were equipped with connectivity features, enabling patients to sync their devices with smartphone apps. This allowed for real-time data tracking and personalization of insulin dosing. The ability to remotely monitor and adjust insulin delivery settings was a trend, particularly for patients who required caregiver support or healthcare professional oversight. For instance, in November 2023, Terumo India, the Indian subsidiary of Terumo Corporation, launched its new Insulin Syringe, a sterile delivery device designed for patients requiring regular insulin injections, enhancing patient comfort and therapy compliance. This syringe, part of Terumo's Life Care Solutions division, features a 3-bevel super-sharp needle with a high-grade silicone surface, ensuring a gentler, more comfortable experience for patients. Additionally, its innovative plunger retention technology prevents spillage and dose wastage. The product is available in both U-40 and U-100 scale markings and offers multiple needle size options. Some insulin delivery devices incorporated smart algorithms that could predict and prevent hypoglycemia or hyperglycemia, offering a personalized approach to glycemic control. Manufacturers focused on creating user-friendly interfaces, making it easier for patients to customize and personalize their device settings.

Segmental Insights

Product Type Insights

Based on Product Type, the Pens emerged as the fastest growing segment in the Indian market for Insulin Delivery Devices during the forecast period. Insulin pens are increasingly preferred by patients due to their ease of use, portability, and convenience. Designed for self-administration, they allow diabetic patients to manage their insulin intake at home without requiring professional assistance. This user-friendly feature has made insulin pens particularly popular in urban and semi-urban areas. The growing prevalence of diabetes in India has significantly driven demand for insulin delivery devices, with more patients opting for insulin therapy. Insulin pens have become the preferred choice due to their precision and simplicity. Technological advancements, including prefilled cartridges, adjustable dosage settings, and enhanced needle design, have improved both the effectiveness and comfort of insulin pens, making them even more appealing to patients and contributing to market growth. The pens' ability to provide better control over insulin dosage and their user-friendly design have also improved patient compliance, leading healthcare providers to increasingly prescribe them for more effective disease management. As self-management and home-based treatments become more common, insulin pens have emerged as a preferred solution for many patients. Their portability and ease of use outside healthcare settings have further driven their popularity and, consequently, the market's expansion.

Distribution Channel Insights

Based on Distribution Channels, Retail Pharmacies emerged as dominating segment in the India Insulin Delivery Devices Market in 2024.  Retail pharmacies are widely distributed across urban and rural areas in India, making insulin and insulin delivery devices easily accessible to a broad population. Patients can purchase these products without having to visit specialized healthcare facilities. Retail pharmacies often have an extensive distribution network, which allows them to reach even remote areas. This network enables the efficient delivery of insulin and insulin delivery devices to many patients. Many insulin products, such as insulin pens and some insulin syringes, are available over the counter in India, which means patients can purchase them directly from retail pharmacies without a prescription. Retail pharmacies provide convenience to patients who may prefer to pick up their insulin and related devices while purchasing other healthcare or household products. Patients can also consult pharmacists for guidance on proper insulin administration. Pharmacists in retail pharmacies can offer basic education and information to patients about insulin therapy, insulin delivery devices, and proper storage, promoting better adherence to treatment plans. 

Download Free Sample Report

Regional Insights

Based on Region, North India emerged as dominating region in the India Insulin Delivery Devices Market in 2024. North India is one of the most densely populated regions in the country. With a higher population, there is a larger pool of potential diabetes patients, creating a significant demand for insulin and insulin delivery devices. North India includes major urban centers such as Delhi, NCR (National Capital Region), and several other rapidly urbanizing cities. Urbanization often leads to lifestyle changes, including dietary habits, which can contribute to a higher prevalence of diabetes. Urban areas also tend to have better access to healthcare services, including diabetes management. The North Indian region is home to some of India's most advanced and well-equipped healthcare facilities, including hospitals, clinics, and specialized diabetes care centers. These institutions are more likely to offer a wide range of insulin delivery devices. North India has a higher concentration of healthcare professionals, including endocrinologists and diabetes educators. This can lead to better diabetes care, including the prescription and use of insulin delivery devices.

Recent Development

• In November 2024, the Foundation for Science Innovation and Development (FSID) at IISc and Honeywell Hometown Solutions India Foundation (HHSIF) partnered to support deep-tech and deep-science startups in med-tech, agri-tech, and environmental sectors. HHSIF, Honeywell India's philanthropic arm, has allocated USD 1 Million in CSR funding, including USD0.28 Million for FY 2023-24. This collaboration aims to foster scientific innovation and social impact. One highlighted startup, Open MedLabs, has developed an affordable insulin pump, InsuFlo, priced at USD 709.14- 945.52, compared to commercial pumps costing USD0.0035- 0.0071 Million. The device, with annual consumables costing just USD 2.36, is patent-protected and set for human trials completion by Q2 2025.
• In August 2024, Abbott announced a strategic partnership with Medtronic to develop an integrated continuous glucose monitoring (CGM) system, utilizing Abbott's cutting-edge FreeStyle Libre technology. This system will seamlessly connect with Medtronic’s automated insulin delivery (AID) and smart insulin pen systems. The integration of Abbott’s CGM sensor with Medtronic’s AID algorithms will enable automatic insulin adjustments to maintain optimal glucose levels. The CGM sensor, developed by Abbott and sold by Medtronic, will be designed for exclusive use with Medtronic devices.
• In April 2024, Sanofi India launched its latest diabetes treatment, Soliqua, following approval from the Central Drugs Standard Control Organisation (CDSCO) in the previous year. Soliqua is a once-daily injectable combination of insulin glargine 100 Units/ml, a long-acting basal insulin, and lixisenatide, a GLP-1 receptor agonist. Priced at USD 21.87 per pen, it provides an affordable option for individuals managing type 2 diabetes mellitus. Soliqua is recommended for adults diagnosed with both obesity and type 2 diabetes mellitus as a therapeutic treatment.

Key Market Players

• Biocon Limited
• India Medtronic Pvt. Ltd.
• Roche Products (India) Pvt. Ltd.
• Becton Dickinson India Private Limited
• Novo Nordisk India Pvt Ltd
• Sanofi Healthcare India Pvt. Ltd.
• Eli Lilly & Co (India) Pvt. Ltd
• Abbott India Ltd
• B. Braun Medical SE

Report Scope:

In this report, the India Insulin Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Insulin Delivery Devices Market, By Product Type:

o   Pens

o   Pumps

o   Pen Needles

o   Others

• India Insulin Delivery Devices Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

o   Others

• India Insulin Delivery Devices Market, By End User:

o   Hospitals & Clinics

o   Homecare

o   Others

• India Insulin Delivery Devices Market, By Region:

o   North India

o   South India

o   East India

o   West India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Insulin Delivery Devices Market.

Available Customizations:

India Insulin Delivery Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Insulin Delivery Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]